US Court Upholds Drug Pricing Regulation Against Pharma Challenge, Removing Legal Safety Net

What the court decided

A US federal court ruled against pharmaceutical industry plaintiffs challenging the Inflation Reduction Act's authority to force drug price negotiations with Medicare. The ruling upholds the government's right to compel manufacturers to negotiate prices, removing a legal argument that had been one of the industry's central strategies for limiting the IRA's pricing provisions.

The pharmaceutical industry has pursued multiple legal challenges to the IRA negotiation program through trade organisations and individual companies. Courts have now consistently found against these challenges. The pattern of rulings narrows the space for a successful legal reversal.

Why this matters for pharma stock valuations

Pharmaceutical valuations implicitly price in an option on the possibility that IRA drug pricing is overturned or significantly modified by the courts. When courts consistently rule against industry challenges, that option loses value. The effect is to move pharma stocks toward pricing in the full regulatory headwind of the IRA as a permanent feature.

For drugs already on the Medicare negotiation list, the ruling is confirmatory rather than new information. For drugs approaching negotiation eligibility, particularly high-revenue growth drugs that companies have been ramping aggressively, the ruling removes hope for legal relief before their eligibility window opens.

Which companies are most directly affected

Merck has the largest near-term exposure. Keytruda is already in the first round of negotiations. A further adverse ruling reinforces that Keytruda's Medicare revenue trajectory is subject to a negotiated cap rather than market pricing. Merck had been one of the more aggressive pharmaceutical companies in legal challenges.

Eli Lilly faces growing exposure as Mounjaro and Zepbound grow toward Medicare spend thresholds. Each successive court ruling makes it more certain that the drug-pricing negotiation framework will govern these drugs when they become eligible, capping their Medicare revenue upside.

AbbVie faces the same structural constraint through Skyrizi and Rinvoq. With Humira already deep in biosimilar erosion, these successor drugs carry most of AbbVie's long-term revenue expectation. Confirmed IRA permanence removes pricing optionality for these future high-revenue products.

What to watch

Any petition to the Supreme Court or remaining circuit-level cases would be the next legal events to monitor. A Supreme Court cert denial would be the clearest signal that the legal avenue is fully exhausted. On the legislative side, any modification of the IRA drug pricing provisions, which remains theoretically possible through Congress, would be the other path for the industry.